Chugai Pharmaceutical Co Ltd
TSE:4519
Chugai Pharmaceutical Co Ltd
Revenue
Chugai Pharmaceutical Co Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Revenue
¥1.2T
|
CAGR 3-Years
1%
|
CAGR 5-Years
11%
|
CAGR 10-Years
10%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Revenue
¥4.6T
|
CAGR 3-Years
10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Revenue
¥1.9T
|
CAGR 3-Years
22%
|
CAGR 5-Years
14%
|
CAGR 10-Years
9%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Revenue
¥2.3T
|
CAGR 3-Years
16%
|
CAGR 5-Years
11%
|
CAGR 10-Years
4%
|
|
|
S
|
Shionogi & Co Ltd
TSE:4507
|
Revenue
¥431.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
5%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Revenue
¥1.9T
|
CAGR 3-Years
14%
|
CAGR 5-Years
8%
|
CAGR 10-Years
4%
|
|
Chugai Pharmaceutical Co Ltd
Glance View
Chugai Pharmaceutical Co., Ltd., a pivotal player in the pharmaceutical industry, finds its roots deeply intertwined with innovations in biotechnology. Established in Tokyo, Chugai has carved out a niche by focusing on the development and distribution of prescription pharmaceuticals tailored to address some of the most challenging medical conditions. The company's collaboration with Roche, a global healthcare leader, has strategically positioned it within the Roche Group, allowing access to an expansive trove of research and development resources. This partnership amplifies Chugai's innovative efforts, particularly in biologics and oncology, where they develop antibodies and therapies that have been instrumental in advancing clinical treatments worldwide. The synergy of Chugai's science-driven approach, coupled with Roche's global reach, has fostered a dynamic research environment that continues to push the boundaries of medical treatment possibilities. Revenue streams for Chugai are primarily anchored in the research, development, and subsequent commercialization of novel pharmaceuticals. The company gains its financial strength through successful product launches, sustained sales of flagship products, and collaborative research agreements. Chugai's extensive pipeline, particularly in the fields of oncology, immunology, and renal diseases, reflects a strategic emphasis on addressing unmet medical needs, with a considerable portion of their earnings reinvested into further research. Additionally, strategically negotiated licensing agreements allow Chugai to bolster its financial health by sharing its innovations with other industry players, maximizing distribution channels while ensuring a steady cash influx. Through this intricate balance of innovation, strategic partnerships, and a robust commercial network, Chugai not only thrives within the competitive pharmaceutical landscape but also contributes significantly to the global healthcare ecosystem.
See Also
What is Chugai Pharmaceutical Co Ltd's Revenue?
Revenue
1.2T
JPY
Based on the financial report for Mar 31, 2025, Chugai Pharmaceutical Co Ltd's Revenue amounts to 1.2T JPY.
What is Chugai Pharmaceutical Co Ltd's Revenue growth rate?
Revenue CAGR 10Y
10%
Over the last year, the Revenue growth was 18%. The average annual Revenue growth rates for Chugai Pharmaceutical Co Ltd have been 1% over the past three years , 11% over the past five years , and 10% over the past ten years .
You don't have any saved screeners yet